An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults

AIDS

Volumn 20, Issue 16, 2006, Pages 2051-2064

  Bartlett, John A ^a,e   Fath, Michael J ^b   DeMasi, Ralph ^c   Hermes, Ashwaq ^b   Quinn, Joseph ^d   Mondou, Elsa ^d   Rousseau, Franck ^d  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b ABBOTT LABORATORIES   (United States)

^c Trimeris Inc   (United States)

^d GILEAD SCIENCES INC   (United States)

^e Box 3152 ^*  (United States)

Author keywords

Antiretroviral therapy; Systematic overview; Treatment naive

Indexed keywords

ABACAVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFECT; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LINEAR REGRESSION ANALYSIS; META ANALYSIS; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PUBLICATION; REVIEW; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIALS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

EID: 33750253867     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000247578.08449.ff     Document Type: Review

References (136)

1. Deng SC, Chen MY, Hsieh SM, Sheng WH, Hsiao CF, Hung CC, Chang SC. Response to efavirenz plus two nucleoside reverse-transcriptase inhibitors in patients with advanced stage human immunodeficiency virus-1 infection in Taiwan. J Microbiol Immunol Infect 2003; 36:10-14.
2. Yeni PG, Hammer SM, Hirsch MS, Saag MS, Schechter M, Carpenter CC, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 2004; 292:251-265.
3. Bartlett JA, DeMasi R, Quinn J, Moxham C, Rousseau F. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS 2001; 15:1369-1377.
4. Brett-Smith H, Reynolds L. 48 week efficacy results: stavudine extended-release (XR) formulation as compared to stavudine immediate-release (IR) formulation. In: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, 2002.
5. Brett-Smith H, Reynolds L, Bessen L, Rutkiewicz V. Two-year analysis of stavudine extended-release/prolonged-release capsules (XR/PRC) as compared to stavudine immediate-release (IR): efficacy and safety. In: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, 2003.
6. Pollard R, Ive P, Farthing C, Whelden M, Thompson S, Brett-Smith H. Stavudine XR vs stavudine IR as part of potent antiretroviral combination therapy: 24-week safety and antiviral efficacy. In: Ninth Conference on Retroviruses and Opportunistic Infections. Seattle, WA; 2002.
7. Van Leeuwen R. Design of the 2NN study: a large-scale, randomized comparison of nevirapine and efavirenz. In: Sixth International Congress on Drug Therapy in HIV Infection, Glasgow, 2002.
8. van Leth F, Hassink E, Phanuphak P, Miller S, Gazzard B, Cahn P, et al. Results of the 2NN Study: a randomized comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine alone, efavirenz alone or both drugs combined, together with stavudine and lamivudine. In: Tenth Conference on Retroviruses and Opportunistic Infections, Boston, 2003.
9. van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004; 363:1253-1263.
10. Robbins G, Shafer R, Smeaton L, De Gruttola V, Pettinelli C, Snyder S, et al. Antiretroviral strategies in naïve HIV+ subjects: comparison of 4-drug versus sequential 3-drug regimens (ACTG 384). In: XIV International AIDS Society Conference, Barcelona, Spain, International AIDS Society, 2002 [abstract LbOr20B].
11. Robbins G, Shafer R, Smeaton L, De Gruttola V, Pettinelli C, Snyder S, et al. Antiretroviral strategies in naive HIVR subjects: comparison of sequential 3-drug regimens (ACTG 384). In: XIV International Aids Society Conference, Barcelona, Spain, 2002 [abstract LbOr20A].
12. Shafer RW, Smeaton LM, Robbins GK, De Gruttola V, Snyder SW, D'Aquila RT, et al. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003;349:2304-2315.
13. Gulick R, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer WA, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004; 350:1850-1861.
14. Gulick RM, Meibohm A, Havlir D, Eron JJ, Mosley A, Chodakewitz JA, et al. Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine 1. AIDS 2003; 17:2345-2349.
15. Gulick RM, Ribaudo HJ, Shikuma CM, Lalama C, Schackman BR, Meyer WA, et al. Three-vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: A randomized controlled trial. JAMA 2006; 296:769-781.
16. Gatell J, Squires K, Piliero P, Sanne I, Wood R, Shelton S, et al. Atazanavir (BMS-232632): absence of serum lipid changes after 48 weeks of treatment in treatment-naive HIV-positive subjects (Trial A1424-007). In: Eighth European Conference on Clinical Aspects and Treatment of HIV Infection, Athens, Greece, 2001.
17. Sanne I, Piliero P, Squires K, Thiry A, Schnittman S. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects 20. J Acquir Immune Defic Syndr 2003; 32:18-29.
18. Squires K, Gatell J, Piliero P, Sanne I, Wood R, Schnittman SM. 48-week safety and efficacy results from a phase II study of a once-daily HIV-1 protease inhibitor (PI), BMS-232632. In: Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, IL; 2001.
19. Bristol-Myers Squibb Company. Reyataz (atazanavir sulfate) capsules prescribing information. New York: Bristol-Myers Squibb Company; 2004.
20. Cahn P, Percival L, Phanuphak P, Sanne I, Kelleher T, Giordano M. Phase II 24-week data from study AI424-008: Comparative results of BMS-232632, stavudine, Lamuvidine as HAART for treatment-naive HIV-infected patients. In: First IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, 2001.
21. Murphy R, Pokrovsky V, Rozenbaum W, Wood R, Percival L, Odeshoo L, Giordano M. Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or ATV: 108-week results of BMS study 008/044. In: Tenth Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2003.
22. Murphy RL, Sanne I, Cahn P, Phanuphak P, Percival L, Kelleher T, Giordano M. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS 2003; 17:2603-2614.
23. Pantaleo G, Sanne I, Cahn P, Percival L, Phanuphak P, Kelleher T, et al. Atazanavir (BMS-232632): 48-week safety and efficacy vs nelfinavir, each in combination with stavudine and lamivudine, in treatment-naive, HIV-positive subjects (A1424-008). In: Eighth European Conference on Clinical Aspects and Treatment of HIV - Infection, Athens, Greece, 2001.
24. Sanne I, Cahn P, Percival L, Phanuphak P, Kelleher T, Giordano M, Pantaleo G. Comparative results (Phase II 48-Week): BMS-232632, stavudine, lamivudine as HAART for treatment-naive HIV(+) patients (AI424-008). In: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), Chicago, IL, 2001.
25. Wood R, Phanuphak P, Cahn P, Pokrovskiy V, Rozenbaum W, Pantaleo G, et al. Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir. J Acquir Immune Defic Syndr 2004; 36:684-692.
26. Bristol Myers Squibb Company. Videx (didanosine) prescribing information. New York: Bristol Myers Squibb Company; 2004.
27. Delfraissy JF, Rivero A, Yakovlev A, Squires K, Thiry A, Giordano M. Comparison of antiretroviral efficacy and safety of atazanavir qd and efavirenz qd with fixed-dose ZDV + 3TC through week 24 (AI424-034). In: Sixth International Congress on Drug Therapy in HIV Infection, Glasgow, UK, 2002.
28. Squires K, Thiry A, Giordano M. Atazanavir (ATV) QD and efavirenz (EFV) QD with fixed-dose ZDV+3TC: comparison of antiviral efficacy and safety through wk 24 (AI424-034). In: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 2002.
29. Gathe J, Benetucci J, Lupo S, Connaughton E, Kelleher T, McLaren C. Comparison of a triple regimen containing once-daily didanosine vs a regimen of ZDV/3TC/NLF. In: 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1999.
30. Badaro R, Gathe J, Grimwood J, McLaren C, Klesczewski K. Evaluation of a triple combination regime containing enteric coated didanosine administered once-daily. In: First IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, Argentina, 2001.
31. Gathe J, Badaro R, Grimwood J, Abrams D, Klesczewski K, McClaren C. Comparison of a triple combination regimen containing an enteric coated formulation of didanosine administered once-daily versus a regimen of combivir plus nelfinavir. In: Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, IL, 2001.
32. Molina J. Once-daily therapy with emtricitabine, didanosine and efavirenz in treatment naïve HIV-infected adults: 48-week follow-up of The ANRS 091 Trial. In: 38th Annual Meeting of the IDSA (Infectious Diseases Society of America), New Orleans, Louisiana, 2000.
33. Molina JF, Journot V, Maillard A, Noe E, Raffi F, Rozenbaum W, et al. and the Montana Study Group. Once-daily combination therapy with emtricitabine, didanosine and efavirenz in treatment naive HIV-infected adults: 96-week follow-up of the ANRS 091 trial. In: Eighth Conference on Retroviruses and Opportunistic Infections, Athens, 2001.
34. Molina JM, Ferchal F, Rancinan C, Raffi F, Rozenbaum W, Sereni D, et al. Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients 2. J Infect Dis 2000; 182:599-602.
35. Molina JM, Ferchal F, Rancinan C, Raffi F, Rozenbaum W, Sereni D, et al. A pilot study of FTC + ddI +efavirenz in treatment-naive HIV-infected adults: a potent and convenient once-a-day HAART(ANRS 091 trial). In: Seventh Conference on Retroviruses and Opportunistic Infections, 2000, [abstract 518].
36. Molina JN, Raffi F, Rozenbaum W, Morlat P, Rancinan C, Journot V, et al. and the Montana Study Group. Once-daily combination therapy with emtricitabine (FTC), didanosine (ddI) and efavirenz in treatment naïve HIV-infected adults: 3-year follow-up of the MONTANA (ANRS091) trial. In: Second IAS Conference on HIV Pathogenesis and Treatment, 2003.
37. Landman R, Schiemann R, Thiam S, Vray M, Canestri A, Mboup S, et al. Once-a-day highly active antiretroviral therapy in treatment-naive HIV-1-infected adults in Senegal. AIDS 2003; 17:1017-1022.
38. Landman R, Thiam S, Canestri A, Delaporte E, Mboup S, Vray M, et al. Long-term evaluation (15 Months) of ddI, 3TC and efavirenz once-daily regimen in naïve patients in Senegal: ANRS 12-04/IMEA 011 study. In: Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 2002.
39. Murphy RL, Katlama C, Johnson V, Squires K, Horban A, Gatell JM, et al. The Atlantic Study: A randomized, open-label trial comparing two protease inhibitor (PI)-sparing antiretroviral strategies versus a standard PI-containing regimen. In: 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1999.
40. van Leeuwen R, Katlama C, Murphy RL, Squires K, Gatell J, Horban A, et al. A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients 9. AIDS 2003; 17:987-999.
41. Avanti Study Group. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients 7. AIDS 2000; 14:367-374.
42. Goebel FD. AVANTI 2. A randomized, double blind, comparative trial to evaluate combination antiretroviral regimens for the treatment of HIV-1 infection: AZT/ 3TC/indinavir in anti-retroviral naive patients. In: Sixth European Conference on Clinical Aspects and Treatment of HIV-Infection, Hamburg, Germany, 1997 [abstract 211].
43. Hill A, Demasi R, Kuhn M. Different analyses give highly variable estimates of HIV-1 RNA undetectability and log reduction in clinical trials. In: Twelfth World AIDS Conference, Geneva, 1998.
44. Clumeck N. Avanti 3: A randomized, double blind, comparative trial to evaluate the efficacy, safety and tolerance of AZT/3TC vs AZT/3TC/nelfinavir in antiretroviral naive patients. In: Fifth Conference on Retrovirus and Opportunistic Infections, Chicago, IL, 1998.
45. Gartland M. AVANTI 3: a randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients. Antivir Ther 2001; 6:127-134.
46. Bartlett JA, Johnson J, Shaefer MS, Herrera G, Sosa N, Rodriguez AE. Abacavir/lamivudine (ABC/3TC) in combination with efavirenz (NNRTI), amprenavir/ritonavir (PI) or stavudine (NRTI): ESS40001(CLASS) preliminary 48 week results. In: 14th International AIDS Conference, Barcelona, Spain, 2002.
47. Gazzard B, DeJesus E, Cahn P, Castillo S, Zhao H, Gordon D, et al. Abacavir (ABC) once daily (OAD) plus lamivudine (3TC) OAD in combination with efavirenz (EFV) OAD is well-tolerated and effective in the treatment of antiretroviral therapy (ART) naive adults with HIV-1 infection (ZODIAC study: CNA30021). In: 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, 2003.
48. Glaxo-Smith-Kline. Ziagen (abacavir sulfate) package insert. Research Triangle Park, NC: Glaxo-Smith-Kline; 2005.
49. Piliero P. Is Abacavir a once daily drug. In: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2003.
50. Fischl M, Greenberg S, Clumeck N, Peters B, Rubio R, Gould J, et al. Ziagen (abacavir, ABC, 1592) combined with 3TC & ZDV is highly effective and durable through 48 weeks in HIV-1 infected antiretroviral-therapy-naive subjects (CNAA3003). In: Sixth Conference on Retroviruses and Opportunistic Infections, Chicago, IL, 1999.
51. Fischl M, Greenberg S, Clumeck N, Peters B, Rubio R, Pobiner B, Verity L. Safety and activity of abacavir (ABC, 1592) with 3TC/ZDV in antiretroviral naïve subjects. In: Twelfth International AIDS Conference, Geneva, 1998.
52. Dejesus E, Herrera G, Teofilo E, Castillo S, Bonny T, Thorpe D, et al. Efficacy and safety of abacavir (ABC) versus zidovudine (ZDV) in antiretroviral therapy naïve adults with HIV-1 infection (Study CNA30024). In: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2003.
53. Staszewski S, Keiser P, Gathe J, Haas D, Montaner J, Hammer S, et al. Ziagen/combivir is equivalent to indinavir/combivir in antiretroviral therapy (ART) naive adults at 24 weeks (CNA3005). In: Sixth Conference on Retroviruses and Opportunistic Infections, Chicago, IL, 1999.
54. Staszewski S, Keiser P, Gathe J, Haas D, Montaner J, Johnson M, et al. Comparison of antiviral response with abacavir/combivir to indinavir/combivir in therapy-naive adults at 48 weeks (CNA3005). In: 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, 1999.
55. Staszewski S, Keiser P, Gathe J, Haas D, Montaner J, Johnson M, et al. Comparison of antiviral response with abacavir/3TC/ZDV to indinavir/3TC/ZDV in therapy naïve adults at 48 weeks (CNA3005). In: Seventh European Conference on Clinical Aspects and Treatment of HIV-Infection, Lisbon, Portugal, 1999.
56. Staszewski S, Keiser P, Montaner J, Raffi F, Gathe J, Brotas V, et al. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial 85. JAMA 2001; 285:1155-1163.
57. Jordan J CP, Vibhagool A. Predictors of adherence and efficacy in HIV-1-infected patients treated with abacavir/combivir (ABC/COM) or indinavir/combivir (IDV/COM): final 48-week dData from CNA3014. 543-T. In: Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, 2002.
58. Vibhagool A, Cahn, P, Schechter, M, Smaill F, Soto-Ramirez L, Carosi G, et al. Abacavir/combivir is comparable to indinavir/Combivir(tm) (iDV/COM) in HIV-1-infected antiretroviral therapy naive adults: preliminary results of a 48-week open-label study (CNA3014). In: First IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, 2001.
59. Vibhagool A, Cahn P, Schechter M, Smaill F, Soto-Ramirez L, Carosi G, et al. Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapynaive adults: results of a 48-week open-label, equivalence trial (CNA3014). Curr Med Res Opin 2004; 20:1103-1114.
60. Matheron S, Descamps D, Boue F, Livrozet JM, Lafeuillade A, Aquilina C, et al. Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial. Antivir Ther 2003; 8:163-171.
61. Podzamczer D, Ferrer E, Consiglio E, Gatell J, Perez P, Perez J, et al. Final 12-month results from the COMBINE study: A randomized, open, mulricenter trial comparing combivier plus nelfinavir or nevirapine in naive patients. In: First IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, Argentina, 2001 [abstract 7].
62. Podzamczer D, Lupo S. Preliminary results of a randomized multicenter study comparing combivir (ZDV/3TC) plus nelfinavir or nevirapine in HIV-infected naive patients (COMBINE Study). In: Seventh Conference on Retroviruses and Opportunistic Infections; 2000 [abstract 510].
63. Dejesus E, Cohen C, Sax P, Nahass R, Morris A, Gothelf S, et al. Efficacy and safety of didanosine-EC (DDI-EC), lamivudine (3TC), and efavirenz (EFV) as a once daily regimen for treatment-naive HIV patients: 24 week interim results from the DART I trial. In: 41st Annual Meeting of IDSA, San Diego, 2003.
64. Ward D, Cohen C, Keiser P, Morris A, Sax P, Dezii C, et al. Efficacy and safety of efavirenz (EFV), lamivudine (3TC), didanosine-EC (DDI-EC), as a once daily regimen for treatment-naïve HIV patients: 48 week results from the DART I trial. In: 15th International AIDS Conference, Bangkok, Thailand, 2004.
65. Felizarta F, Becker S, Bellos N, Jayaweera D, Sands M, Slater L, et al. Adherence and efficacy with a once-daily efavirenz-based regimen: 48 week results from the daily antiretroviral therapy II (DART II) study. In: 15th International AIDS Conference, Bangkok, Thailand, 2004.
66. Jayaweera D, Becker S, Bellos N, Felizarta F, Sands M, Slater L, et al. A once daily efavirenz-based regimen for treatment-naïve HIV patients: 48 week efficacy and safety results from the DART II trial. University of Miami School of Medicine, Miami, FL, United States. In: 15th International AIDS Conference, Bangkok, Thailand, 2004.
67. Haas D, Seekins D, Cooper D, Gallant J, Tashima K, Hicks C, Manion DJ. A phase II, double-blind, placebo-controlled, dose ranging study to assess the antiretroviral activity and safety of efavirenz (EFV, SUSTIVA™, DMP 266) in combination with open-label zidovudine (ZDV) with lamivudine (3TC) at 36 weeks [DMP 266-005]. In: 12th World AIDS Conference, Geneva, 1998.
68. Hicks C, Hass D, Seekins D, Cooper R, Gallant J, Carpenter C, et al. A phase 11, double-blind, placebo-controlled, dose ranging study to assess the antiretroviral activity and safety of DMP 266 (Efavirenz, SUSTIVATM) in combination with open-label zidovudine (ZDV) with lamivudine (3TC) [DMP 266-005]. In: Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, IL, 1998.
69. Manion DJ, Faulkner E, Saxton TD, Labriola DF, Ruiz NM. Durability of response of efavirenz (SUSTIVA™, EFV)-containing regimens: report of the post-control period results of studies with EFV. In: Sixth Conference on Retroviruses and Opportunistic Infections, Chicago, IL, 1999.
70. Manion DJ, Labriola DF, Ruiz NM. Efficacy of efavirenz (SUSTIVA™) containing regimens in patients with baseline plasma HIV-RNA viral loads exceeding 100,000 copies/ml. In: Sixth Conference on Retroviruses and Opportunistic Infections, Chicago, IL, 1999.
71. Cohen C, Elion R, Green S, Sathasivam K, Waterhouse B, Villano S, Rui NM. Sustiva (efavirenz) is highly effective and well tolerated in combination with the nucleosides stavudine and lamivudine (Study DMP 266-043). In: The 40th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, ONT, 2000.
72. Luskin-Hawk R, Cohen C, Lang J, Pegram S, Elion R, Green S, et al. Efavirenz is well-tolerated and highly efficacious in combination with the nucleoside stavudine (d4T) + lamivudine (3TC). In: Infectious Disease Society of America (IDSA); 1999.
73. Domula MR, Wasmuth JC, Jutte A, Fatkenheuer G, Oette M, Theisen A, et al. A comparison of AZT/3TC vs 3TC/d4T and ddI/d4T in combination with efavirenz as first line therapy: efficacy and safety results after 48 weeks. In: Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 2002.
74. 3. Spanish Earth-2 Study. In: Seventh European Conference on Clinical Aspects and Treatment of HIV-Infection. Lisbon, Portugal; 1999.
75. Garcia F, Alonso MM, Romeu J, Knobel H, Arrizabalaga J, Ferrer E, et al. Comparison of immunologic restoration and virologic response in plasma, tonsillar tissue, and cerebrospinal fluid in HIV-1-infected patients treated with double versus triple antiretroviral therapy in very early stages: The Spanish EARTH-2 Study. Early Anti-Retroviral Therapy Study. J Acquir Immune Defic Syndr 2000; 25:26-35.
76. DeJesus E, McCarty D, Farthing CF, Shortino DD, Grinsztejn B, Thomas DA, et al. Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial. Clin Infect Dis 2004; 39:411-418.
77. Bowonwatanuwong C, Mootsikapun P, Supparatpinyo K, Tansuphaswadikul S, Athisegran R, Pasook P, Jones A. A randomised, open label study to investigate abacavir (ABC) andlamivudine (3TC) as once daily (QD)components of a triple combination regimen (EPV40001). In: First IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, 2001.
78. Cahn P, Raffi F, Saag M, Wolff M, Pearce D, Molina JM, et al. Virologic efficacy and patterns of resistance mutations in ART-naïve patients receiving combination therapy with once-daily emtricitabine compared to twice-daily stavudine in a randomized, double-blind, multi-center clinical trial. In: 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2003.
79. Raffi F, Saag M, Cahn P, Wolff M, Pearce D, Molina J, et al. Stavudine plus didanosine and nevirapine in antiretroviralnaive HIV-infected adults: preliminary safety and efficacy results. VIRGO Study Team. In: Second IAS Conference on HIV Pathogenesis and Treatment; 2003.
80. Saag M, Cahn P, Raffi F, Wolff M, Pearce D, Molina JM, et al. A randomized, double-blind, multicenter comparison of emtricitabine QD to stavudine BID. In: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, 2002.
81. Katzenstein TL, Kirk O, Pedersen C, Lundgren JD, Nielsen H, Obel N, et al. The Danish protease inhibitor study: a randomized study comparing the virological efficacy of 3 protease inhibitor-containing regimens for the treatment of human immunodeficiency virus type 1 infection. J Infect Dis 2000; 182:744-750.
82. Gerstoft J, Kirk O, Obel N, Pedersen C, Mathiesen L, Nielsen H, et al. Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine 1. AIDS 2003; 17:2045-2052.
83. Hill A, Moyle G. A meta-analysis of the virologic efficacy of regimens containing four versus three active antiretroviral agents as initial therapy for HIV-1 infection. In: XIII International HIV Drug Resistance Workshop, Tenerife, Canary Islands, 2004.
84. Anekthananon T, Ratanasuwan A, Techasathit W, Sonjai A, Suwanagool S. Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine, and nevirapine (GPO-VIR) for the treatmewnt of HIV-infected patients. In: XV International AIDS Conference, Bangkok, Thailand, 2004.
85. Gallant J, Staszewski S, Pozniak A, Lu B, Miller MD, Coakley DF, Cheng A. Favorable lipid and mitochondrial (mt) DNA profile for tenofovir disoproxil fumarate (TDF) compared to stavudine (d4T) in combination with lamivudine (3TC) and efavirenz (EFV) in antiretroviral therapy (ART) naïve patients: a 48 week interim analysis. In: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 2002.
86. Staszewski S, Gallant J, Pozniak A, Suleiman JMAH, DeJesus E, Lu B, et al. Efficacy and safety of tenofovir DF (TDF) versus stavudine (d4T) when used in combination with lamivudine and efavirenz in antiretroviral naïve patients: 96-week preliminary interim results. In: 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2003.
87. Skowron G, Myers M, Pedneault L, Smiley L, Warburg M, Odorisio M. A protocol to evaluate the safety and efficacy of multidrug combination antiretroviral therapy with zivoduvine (ZDV) and didanosine (ddl) with or without lamivudine (3TC) or nevirapine (NVP) for the treatment of HIV infection. In: 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, ONT, 1997.
88. Saimot AG, Landman R, Damond F, Mathes D, Gaudebout C, Liebowitch J, et al. Stavudine, didanosine, and ritonavir as a triple therapy in antiretroviral-naïve patients: results at 72 weeks. In: 12th World AIDS Conference, Geneva, 1998.
89. Montaner J, Reiss P, Cooper D, Vella S, Dohnanyi C, Harris M, et al. Long-term follow-up of patients treated with nevirapine (NVP) based combination therapy within the INCAS Trial. In: Fifth Conference on Retrovirus and Opportunistic Infections, Chicago, IL, 1998.
90. Montaner JS, Reiss P, Cooper D, Vella S, Harris M, Conway B, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA 1998; 279:930-937.
91. 3. In: XI International Conference on AIDS; 1996.
92. Wood R, Hawkins DA, Moyle G, De Cian W, Ingrosso A, Greenwald C. Second placebo-controlled study in naive individuals confirms the role of delavirdine in highly active antiretroviral, protease-sparing treatment. In: Sixth Conference on Retroviruses and Opportunistic Infections, Chicago, IL, 1999.
93. Gathe J, Podzamczer D, Johnson M, Schwartz R, Yeh V, Travers N, et al. Once-daily vs twice-daily lopinavir/ritonavir in antiretroviral-naive patients: 48-week results. In: 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, 2004.
94. Podzamczer D, Gathe J, Johnson M, Schwartz R, Villacian J, Marsh T, et al. F1/3 - efficacy and safety of once-daily lopinavir/ritonavir vs. twice-daily lopinavir/ritonavir in antiretroviral-naïve patients: 24-week results. In: Ninth European Aids Conference (EACS), Warsaw, Poland, 2003.
95. Eron J, King M, Xu Y, Brun S, Real K, Murphy R, et al. ABT-378/ritonavir (ABT-387/r) Suppresses HIV RNA to >400 copies/ml in 95% of treatment-naive patients and in 78% of PI-experienced patients at 36 weeks. In: 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1999.
96. Gulick R, King M, Brun S, Real K, Murphy R, Hicks C, et al. ABT-378/ritonavir (ABT-378/r) in antiretroviral naive HIV+ patients: 72 weeks. In: Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, 2000.
97. Hicks C, King M, Brun S, Real K, Murphy R, Eron J, et al. ABT-378/ritonavir (ABT-378/R) in antiretroviral naive HIV+ patients: 48 weeks. In: Seventh European Conference on Clinical Aspects and Treatment of HIV-Infection, Lisbon, Portugal, 1999.
98. Landay A, Brun S, King M, Marsh T, Murphy R, Hicks C, et al. Three-year immunologic responses in antiretroviral-naive HIV+ patients treated with lopinavir/ritonavir (Kaletra) based therapy. In: XIV International AIDS Conference, Barcelona, 2002.
99. Murphy R, Brun S, King M, Manning L, Hicks C, Eron J, et al. Lopinavir/ritonavir (Kaletra) in antiretroviral naive HIV+ patients: 4 year follow-up. In: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 2002.
100. Murphy RL, Brun S, Hicks C, Eron JJ, Gulick R, King M, et al. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS 2001; 15:F1-F9.
101. White C, Brun S, King M, Murphy R, Hicks C, Eron J, Sun E. Lopinavir/ritonavir (Kaletra) in antiretroviral naive HIV+ patients: 144 week follow up. In: First IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, Argentina, 2001.
102. Cernohous P, Bernstein B, Mosley J, King M, Bauer E, Sun E. Safety and efficacy of lopinavir/ritonavir in women in a phase III of antiretroviral-naive subjects. In: XIV International AIDS Conference, Barcelona, Spain, 2002.
103. King M, Bernstein B, Cernohous P, Moseley J, Bauer E, Sun E. Impact of baseline CD4 cell count and viral load on durability of virologic response through 96 weeks for lopinavir/ritonavir (LPV/r) and nelfinavir (NFV) in a phase III clinical trial. In: Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, Washington, 2002.
104. Luo M, Boggs R, Bernstein B, Sun E, Ashraf T. Assessing treatment pattern and cost consequence of lopinavir/ritonavir vs nelfinavir therapy in HIV patients. In: Sixth International Congress Drug Therapy in HIV Infection, Glasgow, UK, 2002.
105. Schranz J. A multicenter, open-label, 24-week pilot study with a 24-week extension to evaluate the safety, tolerability and efficacy of indinavir (IDV)-ritonavir (RTV) 800/100 BID combination with D4t plus 3TC in HIV-infected individuals. In: First IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, Argentina, 2001.
106. Nadler J, Rodriguez-French A, Millard J, Wannamaker P. The NEAT Study: GW433908 efficacy and safety in ART- naive subjects, final 48-week analysis. In: 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2003.
107. Rodriguez-French A, Boghossian J, Gray GE, Nadler JP, Quinones AR, Sepulveda GE, et al. The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients. J Acquir Immune Defic Syndr 2004; 35:22-32.
108. Rodriguez-French A, Nadler J. The NEAT Study: GW433908 efficacy and safety in anti-retroviral therapy (ART) naive subjects, preliminary 24-week results. In: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 2002.
109. Vertex Pharmaceuticals Inc. Lexiva (fosamprenavir calcium) prescribing information. Cambridge, MA, USA: Vertex Pharmaceuticals Inc.; 2004.
110. Carr A, Hudson J, Hoy J, Chuah J, French M. Ozcombo I. Control of HIV replication in treatment naive patients in a randomized trial of HAART. In: Sixth Conference on Retroviruses and Opportunistic Infections, Chicago, IL, 1999.
111. Goodgame J, Hanson C, Vafidis I, Stein A, Jablonowski H. Amprenavir (141W94, APV)/3TC/ZDV exerts durable antiviral activity in HIV-1-infected antiretroviral therapy-naive subjects through 48 weeks of therapy. In: 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1999.
112. Goodgame JC, Pottage JC Jr, Jablonowski H, Hardy WD, Stein A, Fischl M, et al. Amprenavir in combination with lamivudine and zidovudine versus lamivudine and zidovudine alone in HIV-1-infected antiretroviral-naive adults. Amprenavir PROAB3001 International Study Team. Antivir Ther 2000; 5:215-225.
113. Schurmann D, Gathe J, Sanne I, Wood I. Efficacy and safety of GW433908/ritonavir once daily in therapy naïve subjects, 48 week results: the SOLO Study. In: Sixth International Congress on Drug Therapy in HIV
114. Squires K. An open-label, randomized, comparative study of stavudine (d4T) + lamivudine (3TC) + indinavir (IDV) versus zidovudine (ZDV) + 3TC + IDV in treatment of HIV-infected patients: START I. In: 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1999.
115. Squires KE, Gulick R, Tebas P, Santana J, Mulanovich V, Clark R, et al. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I). AIDS 2000; 14:1591-1600.
116. Eron J, Peterson D, Murphy R, Pottage J, Mauney J, Schoellkopf N, Stevens M. An open-label, randomized, comparative study of d4t + ddI + IDV versus ZDV + 3TC + IDV in treatment naive HIV-infected patients (START II). In: 12th World AIDS Conference, Geneva, 1998.
117. Eron JJ Jr, Murphy RL, Peterson D, Pottage J, Parenti DM, Jemsek J, et al. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II) 7. AIDS 2000; 14:1601-1610.
118. Sension MG, Farthing C, Shaffer AG, Graham E, Siemon-Hryczyk P, Pilson RS. Challenges of antiretroviral treatment in transient and drug-using populations: the SUN study 86. AIDS Patient Care STDS 2001; 15:129-136.
119. Raffi F, Reliquet V, Ferre V, Besnier JM, Zucman D, Raguin G, et al. d4T + qd ddI + nevirapine (bid or qd) in antiretroviral-naive HIV-1-infected patients: 1-year results of the VIRGO Study. In: 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1999.
120. Reliquet V, Ferre V, Audrain M, Raffi F. Long-termfollow-up of antiretroviral-naive HIV-infected patients treated with D4T + QD DDI + nevirapine (BID OR QD) in the VIRGO Study. In: Eighth European Conference on Clinic Aspects and Treatment of HIV - Infection, Athens, Greece, 2001.
121. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191-201.
122. Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer WA 3rd et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004; 350:1850-1861.
123. Pozniak A, Gallant JE, DeJesus E, Campo R, Arribas J, Gazzard BG, et al. Superior outcome for tenofovir DF, emitricitabine and efavirenz compared to fixed dose zidovudine/lamivudine and EFV in antiretroviral naive patients. In: Third IAS Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, Brazil, 2005 [abstract We.OA 02.02].
124. Bartlett JG, Gallant JE. Medical management of HIV infection. Baltimore: Johns Hopkins University; 2005.
125. DHHS. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services http://aidsinfo.nih.gov/guidelines/guideline-detail.asp Accessed: May 4, 2006.
126. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-129.
127. Phillips A. Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era. AIDS 2004; 18:51-58.
128. Cooper D, Yeni PG. Virologic and immunological outcomes at 3 years following initiation of ART with regimens containing a NNRTI or PI or both: the INITIO trial. In: Twelfth Conference on Retrovirus and Opportunistic Infections, Boston, MA, 2005 [abstract 165 LB].
129. Podzamczer D, Ferrer E, Consiglio E, Gatell JM, Perez P, Perez JL, et al. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study). Antivir Ther 2002; 7:81-90.
130. Robbins GK, De Gruttola V, Shafer RW, Smeaton LM, Snyder SW, Pettinelli C, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003; 349:2293-2303.
131. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999; 341:1865-1873.
132. Bartlett JA, Johnson J, Herrera G, Sosa N, Rodriguez A, Liao Q, et al. Long-term results of initial therapy with abacavir and lamivudine combined with efavirenz, amprenavir/ritonavir, or stavudine. J Acquir Immune Defic Syndr 2006; in press.
133. Gathe JC Jr, Ive P, Wood R, Schurmann D, Bellos NC, DeJesus E, et al. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS 2004; 18:1529-1537.
134. Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346:2039-2046.
135. Bartlett JA, Buda J, von Scheele B, Mauskopf J, Davis E, Elston R, et al. Minimizing resistance consequences after virologic failure on initialcombination therapy: A systematic overview. J Acquir Immune Defic Syndr 2006; 41:323-331.
136. Gallant JE, Rodriguez AE, Weinberg WG, Young B, Berger DS, Lim ML, et al. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J Infect Dis 2005; 192:1921-1930.